CN112063603B - Acetylation modified CNP protein marker molecule related to central nervous senescence and application thereof - Google Patents
Acetylation modified CNP protein marker molecule related to central nervous senescence and application thereof Download PDFInfo
- Publication number
- CN112063603B CN112063603B CN202010482928.3A CN202010482928A CN112063603B CN 112063603 B CN112063603 B CN 112063603B CN 202010482928 A CN202010482928 A CN 202010482928A CN 112063603 B CN112063603 B CN 112063603B
- Authority
- CN
- China
- Prior art keywords
- protein
- cnp
- acetylation
- senescence
- modified
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y301/00—Hydrolases acting on ester bonds (3.1)
- C12Y301/04—Phosphoric diester hydrolases (3.1.4)
- C12Y301/04037—2',3'-Cyclic-nucleotide 3'-phosphodiesterase (3.1.4.37)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
- G01N33/6848—Methods of protein analysis involving mass spectrometry
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/914—Hydrolases (3)
- G01N2333/916—Hydrolases (3) acting on ester bonds (3.1), e.g. phosphatases (3.1.3), phospholipases C or phospholipases D (3.1.4)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2440/00—Post-translational modifications [PTMs] in chemical analysis of biological material
- G01N2440/10—Post-translational modifications [PTMs] in chemical analysis of biological material acylation, e.g. acetylation, formylation, lipoylation, myristoylation, palmitoylation
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2814—Dementia; Cognitive disorders
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Physics & Mathematics (AREA)
- Urology & Nephrology (AREA)
- Genetics & Genomics (AREA)
- Microbiology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Medicinal Chemistry (AREA)
- Food Science & Technology (AREA)
- General Physics & Mathematics (AREA)
- Cell Biology (AREA)
- Pathology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Computational Biology (AREA)
- General Engineering & Computer Science (AREA)
- Analytical Chemistry (AREA)
- Spectroscopy & Molecular Physics (AREA)
- Biophysics (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
- Peptides Or Proteins (AREA)
Abstract
The invention discloses an acetylation modified CNP protein marker molecule related to central nervous senescence and application thereof. The protein marker molecule is CNP protein modified by acetylation of lysine at positions 177 and 401. The upregulation of the acetylation modification of the 177 and 401 lysines on the CNP protein is used as a marker for the detection of senescence in cells or individuals. The invention provides an effective research method and a research direction for exploring the aging process, the occurrence of aging-related diseases and the aging research in the future.
Description
Technical Field
The invention belongs to the technical field of molecular diagnosis medicine, and relates to an acetylation modified CNP protein marker molecule related to central nerve aging and application thereof.
Background
Aging is mainly manifested by the decline of the biochemical and physiological functions of individuals with age, and is a major risk factor for diseases such as cancer, obesity, type 2 diabetes and the like. With improvements in social healthcare services and systems, the reduction in mortality rates of children and pregnant and lying-in women, and improvements in lifestyle and living standards, the average life expectancy of humans has currently exceeded 60 years. The prolongation of Life greatly affects the population structure, and it is expected that the population number will increase from 6.05 million to 20 million around the World between 2000 and 2050 years for 60 years and beyond (World Health Organization, "Life exhibition in creatable by 5 years site 2000, but Health in interests past," http:// www.who.int/media/news/reviews/2016/Health in interests-experience/en.). An increase in aging population will have profound effects on social and economic activities. Although we cannot inhibit the aging process, finding the occurrence of aging as early as possible and delaying aging through certain intervention or treatment will help to reduce the risk of aging-related diseases, improve the quality of life of the elderly, and reduce the burden on families and society. For aging research, a problem to be solved is to find markers (Burkle, Grune, Gonos, & Bohr,2015) that can be quantitatively analyzed for aging, which is also necessary for evaluating the effect of anti-aging treatment.
It is generally believed that aging in mammals has the following 9 characteristics: genome instability, loss of telomeres, epigenetic changes, decreased protein stability, dysregulation of nutrient perception, mitochondrial dysfunction, cellular senescence, stem cell failure, and alterations in cell-cell communication (Lopez-Oti i n, Blasco, Partridge, Serrano, & Kroemer, 2013). Markers that have been found to reflect cellular senescence include: phosphorylation of histone h2a.x (Ser139) (also known as γ -h2a.x, a marker of DNA damage), increased expression of p16INK4A, loss of expression of lamin B1, increased lysosomal content and altered lysosomal activity, among others. In addition, senescent cells are also characterized by extensive chromatin remodeling, most notably the formation of senescence-associated heterochromatin clusters (SAHF) (Freund, Laberge, Demaria, & Campisi, 2012; LaPak & Burd, 2014; Nacarelli, Liu, & Zhang, 2017; Rogakou, Boon, Redon, & Bonner, 1999). Tissue levels are the level of senescence most determined by the overall level of metabolites, such as total homocysteine (tHcy), total Cholesterol, very low, High density lipoprotein density lipoproteins, triglycerides, etc. (Arnesen et al, 1995; Cullen, 2000; Expert Panel on protection & Treatment of High Blood Cholesterol in, 2001; Grundy et al, 2004; Manlio et al, 1992; Verhoef et al, 1996). Partial central nervous system marker proteins may also be used as aging markers, such as beta-amyloid 42(A beta 42), total tau, phosphorylated tau, and F-isoprostane (F2-iso) (Blennow, Vanmechelen, & Hampel, 2001; Galasko et al, 1998; Kim, Jung, Paeng, Kim, & Chung, 2004; Poitou et al, 2005), and the like.
The protein is the material basis of life activity, and the physicochemical properties of the primary structure and the folded higher structure of the protein are the basis of the activity and stability of the protein. Protein post-translational modification (PTM) is the binding of specific chemical groups to amino acid side chains in an enzyme-dependent or enzyme-independent manner, thereby affecting protein structure and function. Enzymatic PTMs include phosphorylation, glycosylation, acetylation, methylation, sumoylation, palmitoylation, biotinylation, ubiquitination, nitration, chlorination, and oxidation/reduction. Whereas non-enzymatic PTMs include glycosylation, nitrosylation, oxidation/reduction, acetylation, and succination (Witze, Old, curing, & Ahn, 2007).
Changes in post-translational modifications of proteins during senescence have been noted for a long time, and it was found that the accumulation of abnormal forms of enzymes is associated with post-translational modifications of proteins with increasing age, and the progressive loss of enzymes that degrade these modifications with increasing age (Stadtman, 1988). Recent studies have also suggested that changes in post-translational modifications of proteins and the accumulation of some covalently modified proteins are markers of biological senescence (Vanhooren et al, 2015). The association of enzyme-dependent and enzyme-independent post-translational glycosylation modification of serum proteins with senescence was first fully explored in the "Mark-Age" project completed by european scientists in 2015 (Burkle et al, 2015). In addition to glycosylation, ubiquitination, methylation and acetylation modifications of proteins may also be associated with senescence (Santos & Lindner, 2017). Accurate analysis of the PTM modification site will therefore provide a possible marker for early diagnosis, prognosis, and detection of the effect of treatment.
Disclosure of Invention
The invention aims to provide an acetylation modified CNP protein marker molecule related to central nervous senescence.
The invention also aims to provide application of the acetylation modified CNP protein marker molecule related to central nervous senescence.
In order to achieve the purpose, the invention is realized by the following technical scheme:
an acetylation modified CNP protein marker molecule related to central nervous senescence is a CNP protein with the 177 th lysine and the 401 th lysine being modified by acetylation.
The amino acid sequence of the CNP protein is as follows:
MNTSFTRKSHTFLPKLFFRKMSSSGAKEKPELQFPFLQDEDTVATLHECKTLFILRGLPGSGKSTLARLILEKYHDGTKMVSADAYKIIPGSRADFSEAYKRLDEDLAGYCRRDIRVLVL
EKDFLPLYFGWFLTKKSSETLRKAGQVFLEELGNHKAFKKELRHFISGDEPKEKLELVSYFGKRPPGVLHCTTKFCDYGKAAGAEEYAQQEVVKRSYGKAFKLSISALFVTPKTAGAQVVLTDQELQLWPSDLDKPSASEGLPPGSRAHVTLGCAADVQPVQTGLDLLDILQQVKGGSQG
the acetylation modified CNP protein marker molecule related to central nervous senescence is applied to cell, tissue, organ or individual senescence degree detection; preferably comprising the steps of:
(1) extracting, purifying and quantifying animal cell or tissue protein;
(2) carrying out enzymolysis on the purified protein;
(3) enriching acetylation modified peptide fragments by using a specific antibody;
(4) quantitatively analyzing acetylation modification of cells or tissue proteins based on a liquid chromatography-mass spectrometry technology;
(5) the degree of aging of a cell, tissue, organ or individual is evaluated by quantitative analysis results.
The animal in the step (1) is a mammal.
The mammals include mice, humans, monkeys, chimpanzees, and the like.
The mice include mice and rats.
The mouse is preferably a C57BL/6 mouse.
The monkey is preferably a cynomolgus monkey.
The orangutan is preferably Sumendortan.
The tissue in step (1) is preferably brain tissue.
The method for quantification in step (1) is preferably a Bradford method.
The enzymolysis in the step (2) is preferably realized by a FASP enzymolysis method.
The specific antibody in step (3) is preferably an anti-acetyl lysine antibody.
The enrichment described in step (3) is preferably achieved by immunoaffinity precipitation.
The quantitative analysis process described in step (4) preferably comprises the steps of:
1) resuspending the enriched acetylated modified peptide fragment, and separating;
2) then, carrying out mass spectrum identification to obtain mass spectrum original data;
3) and (4) performing library searching on the mass spectrum original data through Maxquant software so as to obtain a peptide fragment information list.
The separation described in step 1) is preferably carried out by an easy nano LC1000 system.
The separation conditions are preferably as follows: the fractions were carried out at 500 nL/min by using solution A and solution B as mobile phases and a C18 column (75 μm. times.15 cm, 3 μm) with a separation gradient: 1% B to 3% B in 2 minutes, 3% B to 8% B in the next 8 minutes, 8% B to 20% B in the next 45 minutes, 20% B to 30% B in the next 12 minutes, 30% B to 90% B in the next 1 minute, and then stabilize for 90% B7 minutes; the liquid A is 0.1% (v/v) formic acid-acetonitrile (the solvent is acetonitrile, the solute is formic acid), the liquid B is 0.1% (v/v) formic acid-water (the solvent is water, the solute is formic acid), and the total volume percentage of the liquid A and the liquid B is 100%.
The mass spectrometric identification described in step 2) is preferably carried out using an Orbitrap Fusion Lumos mass spectrometer.
The mass spectrometric identification conditions described in step 2) are preferably mass spectrometric identification in the form of DDA.
The parameters for searching the library in the step 3) are as follows: the sample type is standard, and the multiplex is 1; the protein digestive enzymes are: trypsin; fixing and modifying: carbammidomethyl (C); the variable modifications are acetyl (K), Deamidino (N), Deamidino (NQ); the minimum peptide length is 6; the mismatch rate (FDR) threshold of the peptide fragment and the protein is less than 0.01; the variable modifications used for Protein quantification are oxidation (M), Acetyl (Protein N-term), peptide fragment unique.
The criteria for the evaluation described in step (5) are preferably as follows: the total acetylation modification upregulation degree and the senescence degree of the acetylation modified CNP protein marker molecules related to central nervous senescence are positively correlated, namely, the acetylation modification upregulation degree and the senescence degree of the 177 th lysine and the 401 th lysine are positively correlated.
The acetylation modified CNP protein marker molecule related to central nerve aging is applied to the preparation of a kit for predicting aging-related degenerative diseases.
In the application, the aging degree of the biological sample is judged by determining the molecular acetylation modification degree of the marker molecules in the biological sample.
The determination of the degree of molecular acetylation modification of the CNP protein marker molecule can be achieved by a method or a device for determining the expression level of the related molecule and the acetylation level of the protein in a sample.
The acetylation modified CNP protein marker molecule related to the central nervous senescence is applied to the preparation of drugs for preventing and/or treating degenerative diseases related to senescence.
The application is to use the acetylation modified CNP protein marker molecule related to central nervous senescence as a drug target.
Compared with the prior art, the invention has the following advantages and effects:
the invention provides a biomarker related to aging and a detection method, and CNP (2', 3' -cyclic nucleotide 3' -phosphodiesterase) is used for acetylation modification up-regulation of K177 and K401 sites in aged mouse brain and is used as a marker for cell or individual aging detection. The invention provides an effective research method and a research direction for exploring the aging process, the occurrence of aging-related diseases and the aging research in the future.
Drawings
Fig. 1 is a technical route diagram of the present invention.
FIG. 2 is a secondary spectrum of the peptide fragments LK (ac) PGLEK and GK (ac) PVPIHGSR in which CNP K177 and K401 are located, which is identified by mass spectrometry; wherein a is a secondary spectrum of the peptide fragment of K177 in the sample Y3; b is a secondary spectrum detected by K177 in sample O3; c is a secondary spectrum detected by K401 in a Y3 sample.
FIG. 3 is a graph of the relative quantification of the acetylation of CNP K177 and K401 in different groups of mouse brains in mass spectrometry; wherein a is a relative quantitative result; b is a histogram of the corresponding statistical results.
FIG. 4 is an ion flow diagram and a peak area statistical result diagram of a peptide fragment LK (ac) PGLEK in which CNP K177 is located in each sample identified by mass spectrometry; wherein a is an ion flow graph of the peptide fragment LK (ac) PGLEK in each sample; b is the corresponding peak area of the peptide fragment LK (ac) PGLEK in each sample; c is a histogram of statistical results of the b picture.
FIG. 5 is an ion flow diagram and a peak area statistical result diagram of a peptide segment GK (ac) PVPIHGSR in which CNP K401 is identified by mass spectrometry in each sample; wherein a is an ion flow diagram of a peptide segment GK (ac) PVPIHGSR in each sample; b is the corresponding peak area of peptide segment GK (ac) PVPIHGSR in each sample; c is a histogram of statistical results of the b picture.
Fig. 6 is an ion flow graph and a peak area statistical result graph of the CNP nonacetylated peptide segment GGSQGEAVGELPR identified by mass spectrometry in each sample; wherein a is the ion flow map of peptide segment GGSQGEAVGELPR in each sample; b is the corresponding peak area of peptide fragment GGSQGEAVGELPR in each sample; c is a histogram of statistical results of the b picture.
FIG. 7 is a graph showing the results of CoIP verification of mice in different groups; wherein a is a co-immunoprecipitation and Western blot verification result graph; b is a histogram of statistical results of the a diagram.
Detailed Description
The present invention will be described in further detail with reference to examples and drawings, but the present invention is not limited thereto. The technical route of the invention is shown in figure 1.
The reagents and the preparation method related in the embodiment of the invention are as follows:
1mol/L Tris HCl pH 8.0 solution: 12.11g Tris base (Tris-base) was dissolved in pure water, adjusted to pH 8.0 with concentrated hydrochloric acid, and made up to 100ml ultrapure water.
4% chloral hydrate: 0.4g of chloral hydrate was weighed out, dissolved in distilled water and diluted to 10 ml with distilled water.
8mol/L urea buffer: 48.048g of urea granules were weighed out, 5ml of Tris HCl (pH 8.0) solution with a concentration of 1mol/L was added, and the volume of ultrapure water was adjusted to 100 ml.
1mol/L Dithiothreitol (DTT) solution: weighing 15.42g of dithiothreitol, adding ultrapure water to dilute the dithiothreitol into 100ml, dividing the dithiothreitol into small parts, and storing the small parts at-20 ℃.
1mol/L Iodoacetamide (IAA) solution: 0.185g IAA was weighed into 1ml urea buffer with a concentration of 8mol/L until complete dissolution.
50mmol/L NH4HCO3: 2g of ammonium bicarbonate is weighed and ultrapure water is added to the solution until the volume is 50 ml.
1 × PBS: weighing 8g NaCl, 0.2g KCl and 1.44g Na2HPO4And 0.24g KH2PO4Dissolving in 800ml distilled water, adjusting pH value of the solution to 7.4 with HCl, and adding distilled water to constant volume to 1L.
0.05% PBST: 0.5mL of Tween-20 was aspirated, and 1L of PBS buffer was added to the solution to obtain a volume of 1L.
1% acetonitrile, 0.1% trifluoroacetic acid solution (v/v): acetonitrile and trifluoroacetic acid are added into ultrapure water according to the volume ratio and then are shaken up, and the final volume is 500 ml.
40% acetonitrile, 0.1% trifluoroacetic acid solution (v/v): acetonitrile and trifluoroacetic acid were added to ultrapure water in a volume ratio, followed by shaking to give a final volume of 500 ml.
NETN buffer solution: 50mM Tris, 1mM EDTA, 100mM NaCl, 0.5% Nonidet P-40 (ethylphenylpolyethylene glycol), pH 8.0.
ETN buffer 100mM NaCl, 1mM EDTA, 50mM Tris, pH 8.0.
Example 1 sample preparation prior to Mass Spectrometry identification
Extraction of C57BL/6 mouse brain protein
1) The C57BL/6 mice (Experimental animals center of Guangzhou university of traditional Chinese medicine) are divided into three groups, including three young mouse groups (Y1 group, Y2 group, Y3 group, mouse age 2 months) and three old mouse groups (O1 group, O2 group, O3 group, mouse age 16 months); each group had 6 mice.
2) Each mouse is anesthetized by 4% chloral hydrate intraperitoneal injection according to 0.1mL/kg, the abdominal cavity is dissected, after the heart is exposed, the heart is perfused by 1 XPBS buffer solution, and the brain tissue is dissected and weighed;
3) placing the brain tissue in 8mol/L urea buffer solution (the final concentration of the brain tissue is 20mg/mL), and homogenizing by a glass homogenizer to obtain brain tissue homogenate;
4) homogenates of brain tissue are sonicated: the power is 30w, the crushing lasts for 10s, the interval is 10s, and 5 cycles are carried out to obtain brain tissue lysate;
5) centrifuging the brain tissue lysate for 30min at 13000g for 2 times; taking the supernatants of the two times, and mixing;
6) protein concentration was quantified using the Bradford method (Bradford protein concentration assay kit purchased from petunia, product No. P0006; the specific operation steps are carried out according to the instruction).
Enzymatic hydrolysis of FASP
1) Respectively taking the amount of the cerebroprotein of each group of young and old mice to be 2mg, and adding 8mol/L urea buffer solution to 2mL (namely adjusting the concentration of the cerebroprotein to be 1.0mg/mL) to obtain protein suspension;
2) the protein suspension was added to a 10kD 4mL ultrafiltration tube (Millipore Ultrafiltration centrifuge tube 4mL/10 kD)Ultra-4, 2mg brain protein amount/tube), sleeving an ultrafiltration tube in a 15ml centrifuge tube, and centrifuging at 4000g and 24 ℃ until the liquid in the upper chamber of the tube (the upper chamber is an ultrafiltration tube) is less than 100 mu L;
3) adding 1mol/L DTT solution into the upper chamber until the final concentration of DTT is about 20mmol/L, shaking, mixing, air-bathing at 37 deg.C for 1.5h, centrifuging at 4000g and 24 deg.C until the volume of liquid in the upper chamber is less than 100 μ L;
4) pouring out the liquid in the lower chamber of the ultrafiltration tube, adding 1mol/L IAA solution into the upper chamber until the final concentration of the IAA is about 0.1mol/L, shaking, mixing uniformly, keeping out of the sun for 20min at normal temperature, centrifuging under the same conditions until the residual liquid is less than 50 mu L;
5) 50mmol/L NH for upper chamber protein4HCO3Washing and replacing the solution with 50mmol/L NH4HCO3After that, pancreatin was added in a ratio of 1:100, i.e. 50mmol/L NH per tube at 2mL (same volume of the original protein)4HCO3Adding 20 mu g of pancreatin; the lower chamber was also charged with 1ml of 50mmol/L NH4HCO3(ii) a Incubating for 16h at 37 ℃, replacing a new collecting pipe to collect centrifuged liquid, namely a total peptide fragment mixture, and pumping the peptide fragments by a freeze dryer;
6) desalting the peptide segment: the resulting dried peptide fragment was dissolved in phase A (1% acetonitrile, 0.1% trifluoroacetic acid in water) and loaded onto an equilibrated 4.6mmC18 analytical column (Agilent 1200 HPLC). Washing 1ml/min of phase A for 10 min to remove salts and other impurities from the sample, eluting with 1ml/min of phase B (40% acetonitrile, 0.1% trifluoroacetic acid solution) for 5 min and collecting the elution peak, and freeze-drying the collected eluate to obtain purified peptide fragment for next immunoaffinity precipitation.
3. Immunoaffinity precipitation enrichment of acetylated peptide fragments
1) Pipetting 30. mu.L of antibody-coated agarose beads (Pan acetylated antibody-conjugated resin, Pan anti-acetyllysine conjugated agarose beads, PTM BIO, PTM-104) with a pipette, placing in a small filter tube and sleeving on an EP tube, washing the agarose beads with pre-cooled 1 XPBS buffer, centrifuging 500g for 15s, and repeating three times;
2) dissolving the dried peptide fragment with NETN buffer solution, adding into the washed agarose beads, plugging the lower surface of the filter tube with a plug, sealing the cover with a sealing film, fixing on a rotary mixer, and rotationally mixing at 4 deg.C overnight;
3) taking the incubated agarose beads out of the refrigerator the next day, taking a clean EP tube, removing a plug below the filter tube, and centrifuging the liquid into the EP tube; adding 0.5ml of NETN buffer solution into a filter tube, turning upside down and uniformly mixing, 500g, centrifuging for 15s, and washing twice; adding 0.5ml of ETN buffer solution into a filter tube, reversing the upper part and the lower part, uniformly mixing, washing twice under the same centrifugal condition; adding 0.5ml of deionized water or ultrapure water into the filter tube, and washing twice according to the steps; adding 100 μ L of Elution Buffer (Elution Buffer) into the filter tube, inverting for 1min, 500g, centrifuging for 15s, repeating twice again, and collecting the volume of 300 μ L in total;
4) the collected liquid is drained and stored at-20 ℃ to obtain the acetylated peptide fragment.
Example 2 LC-MS/MS identification and data searching
LC-MS/MS identification
1) The enriched peptides were not fractionated and were directly subjected to nanoLC-MS/MS analysis using 0.1% formic acid-acetonitrile (a) and 0.1% formic acid-water (B) as mobile phases, and the peptides of each sample were resuspended in mass spectrometry mobile phase a solution and separated by EasyNano LC1000 system (San Jose, Thermo Fisher) at 500 nL/min on a C18 column (75 μm × 15cm, 3 μm); the flow-through linear gradient is shown in table 1:
TABLE 1 LC-MS/MS elution conditions
Time/min | Flow rate (nL/min) | A%(v/v) | B%(v/v) |
0:00 | 500 | 99 | 1 |
2:00 | 500 | 97 | 3 |
10:00 | 500 | 92 | 8 |
55:00 | 500 | 80 | 20 |
67:00 | 500 | 70 | 30 |
68:00 | 500 | 10 | 90 |
75:00 | 500 | 10 | 90 |
2) Mass spectrometric identification of peptide fragments was performed using an Orbitrap Fusion Lumos (Bremen, Thermo Fisher) mass spectrometer by means of DDA: the scanning period is 3s, the MS1 parent ion scanning range is m/z 350-: starting at 100 m/z. Other parameter settings were as follows: the MS1 and MS2 resolutions were set to 120K and 30K, respectively; with Automatic Gain Control (AGC), MS1 and MS2 are 1e6 and 1e5, respectively; the ion screening window is a quadrupole rod, and is 1.6 m/z; fragmentation mode: HCD, Normalized Collision Energy (NCE) 32; the dynamic exclusion time was 20 s. Secondary maps of the peptide fragments LK (ac) PGLEK and GK (ac) PVPIHGSR in which the 177 th and 401 th lysines of CNP are identified by mass spectrum are shown in FIG. 2. The peptide segment is broken into ions with different mass-to-charge ratios after being detected by mass spectrometry of different b and y ion pairs, and the theoretical mass of the amino acid composition of the peptide segment is met.
2. Mass spectrometry result library search
Mass spectra raw data each set of treatments was pooled by Maxquant (version 1.6.3.3) software, protein sequence database from Uniprot Mus musculus (mouse) containing 10090 protein sequences, the pooling parameters were set to: 1) the sample type is standard, and the multiplex is 1; 2) the protein digestive enzymes are: trypsin; 3) fixing and modifying: carbammidomethyl (C); 4) the variable modifications are acetyl (K), Deamidino (N), Deamidino (NQ); 5) the minimum peptide length is 6; 6) the mismatch rate (FDR) threshold of the peptide fragment and the protein is less than 0.01; 7) the parameters of modified peptide fragment for Protein quantification are oxidation (M), Acetyl (Protein N-term), and peptide fragment for quantification is unique, and the result is used as the change of Protein expression.
Example 3 Mass Spectrometry results with increased CNP acetylation levels
In the Maxquant search library results table, the intensity value of each site in the acetyl (k) sites. txt table is corrected by the total ion current intensity between each sample, and the corrected intensity value is used as the quantification of the acetylated site in each sample. Similarly, each protein intensity value in the protein groups. txt table was corrected by the total ion flux intensity between each sample, and the corrected intensity value was used as a quantitative value for the CNP protein expression level in each sample. The multiple of the intensity difference of the CNP acetylation sites and the multiple of the protein expression difference are counted by using GraphPad Prism software, and the corresponding p-value is tested by t-tests. Meanwhile, the change of acetylation modification was corrected by the change of abundance of non-acetylated proteins to eliminate the change of acetylation modification caused by the change of protein expression amount, and the result is shown in fig. 3. The O-to-Y ratios of peptide fragments of acetylated K177 and K401 are respectively 2.19 and 3.19(p is less than 0.05), and the O-to-Y ratios of acetylated K177 and K401 are respectively 2.57 and 3.7(p is less than 0.05 and p is less than 0.01) after protein abundance correction.
In order to further analyze the changes of expression of the CNP proteins acetylated K177 and K401 in O and Y, an xcalibur software (Thermo scientific) is adopted to directly find out an extracted ion flow graph of the CNP K177 and K401 acetylated peptide segments in the original data. Fig. 4 and 5 show the peak area plots, peak area statistics, and histograms for CNP K177 and K401 acetylated peptide fragments in each sample, respectively, and the results show that acetylation of K177 is increased in O relative to Y (p < 0.0001). Fig. 6 is a peak plot of the nonacetylated peptide fragment GGSQGEAVGELPR in CNP in each sample, which was significantly down-regulated in O (p <0.05) relative to the Y sample.
Example 4 verification of Mass Spectrometry results by Co-immunoprecipitation (CoIP)
160. mu.g of brain protein samples from aged (O) and young (Y) mice were prepared, 20. mu.L of Antibody-coated Agarose Beads (Pan PTM Antibody Conjugated Agarose Beads, Lysine acetic, PTM BIO, PTM-104) were pipetted separately, washed 3 times with PBS, and added to the sample proteins followed by rotary incubation at 4 ℃ overnight. The next day, the cells were removed from the freezer, centrifuged at 800g for 5 minutes, the supernatant was discarded, the pellet was washed 5 times with 0.05% PBST, the target protein was eluted with 0.2% formic acid, the supernatant was centrifuged, and the supernatant was vacuum-dried and then subjected to Western blot analysis using a 2 Xloading buffer in a boiling water bath for 5 minutes, using a primary antibody against CNP (Cell Signaling Technology,5664S) and a secondary antibody against mouse IgG (CST, 7076S). Results as shown in fig. 7, CNP bars enriched with pan-acetylated antibodies in group O and group Y were corrected by CNP of Input, respectively, and the results showed significant upregulation of CNP acetylation.
The above embodiments are preferred embodiments of the present invention, but the present invention is not limited to the above embodiments, and any other changes, modifications, substitutions, combinations, and simplifications which do not depart from the spirit and principle of the present invention should be construed as equivalents thereof, and all such changes, modifications, substitutions, combinations, and simplifications are intended to be included in the scope of the present invention.
Sequence listing
<110> river-south university
<120> acetylation modified CNP protein marker molecule related to central nervous senescence and application thereof
<160> 1
<170> SIPOSequenceListing 1.0
<210> 1
<211> 420
<212> PRT
<213> mouse (Mus musculus)
<220>
<223> amino acid sequence of CNP protein
<400> 1
Met Asn Thr Ser Phe Thr Arg Lys Ser His Thr Phe Leu Pro Lys Leu
1 5 10 15
Phe Phe Arg Lys Met Ser Ser Ser Gly Ala Lys Glu Lys Pro Glu Leu
20 25 30
Gln Phe Pro Phe Leu Gln Asp Glu Asp Thr Val Ala Thr Leu His Glu
35 40 45
Cys Lys Thr Leu Phe Ile Leu Arg Gly Leu Pro Gly Ser Gly Lys Ser
50 55 60
Thr Leu Ala Arg Leu Ile Leu Glu Lys Tyr His Asp Gly Thr Lys Met
65 70 75 80
Val Ser Ala Asp Ala Tyr Lys Ile Ile Pro Gly Ser Arg Ala Asp Phe
85 90 95
Ser Glu Ala Tyr Lys Arg Leu Asp Glu Asp Leu Ala Gly Tyr Cys Arg
100 105 110
Arg Asp Ile Arg Val Leu Val Leu Asp Asp Thr Asn His Glu Arg Glu
115 120 125
Arg Leu Asp Gln Leu Phe Glu Met Ala Asp Gln Tyr Gln Tyr Gln Val
130 135 140
Val Leu Val Glu Pro Lys Thr Ala Trp Arg Leu Asp Cys Ala Gln Leu
145 150 155 160
Lys Glu Lys Asn Gln Trp Gln Leu Ser Ala Asp Asp Leu Lys Lys Leu
165 170 175
Lys Pro Gly Leu Glu Lys Asp Phe Leu Pro Leu Tyr Phe Gly Trp Phe
180 185 190
Leu Thr Lys Lys Ser Ser Glu Thr Leu Arg Lys Ala Gly Gln Val Phe
195 200 205
Leu Glu Glu Leu Gly Asn His Lys Ala Phe Lys Lys Glu Leu Arg His
210 215 220
Phe Ile Ser Gly Asp Glu Pro Lys Glu Lys Leu Glu Leu Val Ser Tyr
225 230 235 240
Phe Gly Lys Arg Pro Pro Gly Val Leu His Cys Thr Thr Lys Phe Cys
245 250 255
Asp Tyr Gly Lys Ala Ala Gly Ala Glu Glu Tyr Ala Gln Gln Glu Val
260 265 270
Val Lys Arg Ser Tyr Gly Lys Ala Phe Lys Leu Ser Ile Ser Ala Leu
275 280 285
Phe Val Thr Pro Lys Thr Ala Gly Ala Gln Val Val Leu Thr Asp Gln
290 295 300
Glu Leu Gln Leu Trp Pro Ser Asp Leu Asp Lys Pro Ser Ala Ser Glu
305 310 315 320
Gly Leu Pro Pro Gly Ser Arg Ala His Val Thr Leu Gly Cys Ala Ala
325 330 335
Asp Val Gln Pro Val Gln Thr Gly Leu Asp Leu Leu Asp Ile Leu Gln
340 345 350
Gln Val Lys Gly Gly Ser Gln Gly Glu Ala Val Gly Glu Leu Pro Arg
355 360 365
Gly Lys Leu Tyr Ser Leu Gly Lys Gly Arg Trp Met Leu Ser Leu Thr
370 375 380
Lys Lys Met Glu Val Lys Ala Ile Phe Thr Gly Tyr Tyr Gly Lys Gly
385 390 395 400
Lys Pro Val Pro Ile His Gly Ser Arg Lys Gly Gly Ala Met Gln Ile
405 410 415
Cys Thr Ile Ile
420
Claims (7)
1. An acetylation modified CNP protein marker molecule related to aging, which is characterized in that: the aging-related acetylated modified CNP protein marker molecules are CNP proteins of which the 177 th lysine and the 401 th lysine are acetylated modified; the amino acid sequence of the CNP protein is shown as SEQ ID NO. 1.
2. Use of the senescence-associated acetylated modified CNP protein marker molecule of claim 1 in the detection of the degree of senescence in cells, tissues, organs or individuals for non-diagnostic and therapeutic purposes.
3. Use according to claim 2, characterized in that it comprises the following steps:
(1) extracting and purifying proteins of animal cells or tissues;
(2) carrying out enzymolysis on the purified protein;
(3) enriching acetylation modified peptide fragments by using a specific antibody;
(4) quantitatively analyzing acetylation modification of cells or histones based on a liquid chromatography-mass spectrometry technology;
(5) the degree of aging of a cell, tissue, organ or individual is evaluated by quantitative analysis results.
4. Use according to claim 3, characterized in that:
the animals in the step (1) include mice, humans, monkeys and chimpanzees;
the tissue in the step (1) is brain tissue;
the enzymolysis in the step (2) is realized by adopting an FASP enzymolysis method;
the enrichment described in step (3) is achieved by immunoaffinity precipitation.
5. Use according to claim 4, characterized in that:
the mice comprise mice and rats;
the monkey is a cynomolgus monkey;
the orangutan is Sumengkangtan.
6. Use according to claim 3, characterized in that:
the specific operation of the quantitative analysis process in the step (4) is as follows:
1) resuspending the enriched acetylated modified peptide fragment, and separating;
2) then, carrying out mass spectrum identification to obtain mass spectrum original data;
3) searching the mass spectrum original data through Maxquant software to obtain a peptide fragment information list;
the criteria for the evaluation described in step (5) are as follows: the acetylation modification up-regulation degree of lysine 177 and lysine 401 of CNP protein is positively correlated with senescence degree.
7. Use according to claim 6, characterized in that:
the separation in step 1) is carried out by an easy Nano LC1000 system;
the mass spectrometric identification described in step 2) uses an Orbitrap Fusion Lumos mass spectrometer;
the parameters for searching the library in the step 3) are as follows: the sample type is standard, and the multiplex is 1; the protein digestive enzymes are: trypsin; fixing and modifying: carbammidomethyl C; the variable modification is Acetyl K, Deamidination N, Deamidination NQ; the minimum peptide length is 6; the mismatch rate threshold of the peptide fragment and the protein is less than 0.01; the peptide fragment used for Protein quantification is modified into Oxidation M, Acetyl Protein N-term, and the peptide fragment is unique.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010482928.3A CN112063603B (en) | 2020-06-01 | 2020-06-01 | Acetylation modified CNP protein marker molecule related to central nervous senescence and application thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010482928.3A CN112063603B (en) | 2020-06-01 | 2020-06-01 | Acetylation modified CNP protein marker molecule related to central nervous senescence and application thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
CN112063603A CN112063603A (en) | 2020-12-11 |
CN112063603B true CN112063603B (en) | 2022-05-06 |
Family
ID=73656108
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202010482928.3A Active CN112063603B (en) | 2020-06-01 | 2020-06-01 | Acetylation modified CNP protein marker molecule related to central nervous senescence and application thereof |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN112063603B (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114716528A (en) * | 2022-03-18 | 2022-07-08 | 孙英贤 | Deacetylation modified Septin4 protein and pharmaceutical application thereof |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108144062A (en) * | 2017-12-15 | 2018-06-12 | 上海交通大学医学院 | Regulate and control SENP1 phosphorylation modifications compound and SIRT3 SUMOization modified compound and its application |
-
2020
- 2020-06-01 CN CN202010482928.3A patent/CN112063603B/en active Active
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108144062A (en) * | 2017-12-15 | 2018-06-12 | 上海交通大学医学院 | Regulate and control SENP1 phosphorylation modifications compound and SIRT3 SUMOization modified compound and its application |
Non-Patent Citations (3)
Title |
---|
Cardiac troponin I R193H mutant interacts with HDAC1 to repress phosphodiesterase 4D expression in cardiomyocytes;Weian Zhao et al.;《Genes Dis》;20200110;第569-579页 * |
Valproic acid synergistically enhances the cytotoxicity of gossypol in DU145 prostate cancer cells: An iTRTAQ-based quantitative proteomic analysis;Dong-yun Ouyanga et al.;《J O U R N A L O F P R O T E O M I C S》;20110605;第2180-2193页 * |
赖氨酸乙酰化调控细胞代谢的机制;王义平等;《专刊:生物大分子动态修饰》;20180430;第447-453页 * |
Also Published As
Publication number | Publication date |
---|---|
CN112063603A (en) | 2020-12-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN112063599B (en) | Acetylation modified SIRT2 protein marker molecule related to central nervous senescence and application thereof | |
Chiou et al. | Clinical proteomics: current status, challenges, and future perspectives | |
Matysiak et al. | Shotgun proteome analysis of honeybee venom using targeted enrichment strategies | |
CN107449831A (en) | The purposes of alzheimer's disease protein marker | |
Slagboom et al. | Analytical strategies in venomics | |
Abd El-Aziz et al. | Advances in venomics: Modern separation techniques and mass spectrometry | |
AU2014229064A1 (en) | Method for replacing biomarkers of protein kinetics from tissue samples by biomarkers of protein kinetics from body fluids after isotopic labeling in vivo | |
Pietrowska et al. | LC‐MS‐based metabolic fingerprinting of aqueous humor | |
CN108948176B (en) | Osteopontin characteristic peptide and application thereof | |
CN112063603B (en) | Acetylation modified CNP protein marker molecule related to central nervous senescence and application thereof | |
CN113777178A (en) | Proteomics background library based on mixed spectrogram library, and construction method and application thereof | |
Brill et al. | Comprehensive proteomic analysis of Schizosaccharomyces pombe by two-dimensional HPLC-tandem mass spectrometry | |
Zhu et al. | Analysis of human serum phosphopeptidome by a focused database searching strategy | |
Yang et al. | Analysis of the human urine endogenous peptides by nanoparticle extraction and mass spectrometry identification | |
CN110308227B (en) | Plasma metabonomics analysis method for patient with primary osteoporosis based on sleep disorder | |
Li et al. | Shotgun proteomic analysis using human serum from type 2 diabetes mellitus patients | |
CN111141863B (en) | Application of reagent of depression diagnosis marker in preparation of depression diagnosis kit | |
CN112062826A (en) | Acetylation modified H2B protein marker molecule related to central nervous senescence and application thereof | |
Liu et al. | Authentication of three main commercial Pheretima based on amino acids analysis | |
Guan et al. | Detection and confirmation of α-cobratoxin in equine plasma by solid-phase extraction and liquid chromatography coupled to mass spectrometry | |
Govorukhina et al. | Influence of clotting time on the protein composition of serum samples based on LC–MS data | |
Cai et al. | Strategies for characterization of low-abundant intact or truncated low-molecular-weight proteins from human plasma | |
CN113721026A (en) | Application of 37 proteins as biomarkers in preparation of products for diagnosing or assisting in diagnosing depression | |
KR20200038449A (en) | A method of isolation of protein and lipid using zwitterionic detergents and the use thereof | |
Zhu et al. | Use of two-dimensional liquid fractionation for separation of proteins from cell lysates without the presence of methionine oxidation |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |